Trial Profile

Ibrutinib in Steroid Refractory Autoimmune Hemolytic Anemia: ELaboration of Treatment Approach

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 21 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ibrutinib (Primary) ; Rituximab (Primary)
Indications Autoimmune haemolytic anaemia; Chronic lymphocytic leukaemia; Pure red cell aplasia
Focus Therapeutic Use
Acronyms ISRAEL

Most Recent Events

01 Jul 2023 Results assessing study of ibrutinib and rituximab in patients with relapsed/refractory to steroids AIHA/PRCA and underlying CLL were published in the Leukemia.
08 Jan 2020 Planned End Date changed from 31 Mar 2020 to 31 Mar 2022.
08 Jan 2020 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com